Korean companies eyes capecitabine market

As the re-examination of capecitabine is to be expired on July 30, several drug makers, such as Ildong, Boryung, Daewoong, Dong-A and Samyang Corporation, are setting their sights on the domestic capecitabine market valued at 10.9 billion won last year.

Capecitabine is an oral drug marketed by Roche as Xeloda. It is used in the treatment of metastatic breast and colorectal cancers. Capecitab...